Medifast (NYSE:MED - Get Free Report) released its quarterly earnings results on Monday. The specialty retailer reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04), Zacks reports. The company had revenue of $115.73 million for the quarter, compared to analyst estimates of $114.85 million. Medifast had a return on equity of 10.64% and a net margin of 0.35%. Medifast updated its Q2 2025 guidance to -0.550-0.000 EPS.
Medifast Stock Performance
Shares of NYSE:MED traded up $0.29 during trading hours on Friday, hitting $13.27. The stock had a trading volume of 266,292 shares, compared to its average volume of 307,303. The stock's fifty day simple moving average is $13.38 and its 200 day simple moving average is $15.99. The firm has a market capitalization of $145.85 million, a price-to-earnings ratio of 73.72 and a beta of 1.05. Medifast has a 1-year low of $11.57 and a 1-year high of $27.18.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on MED. StockNews.com raised shares of Medifast from a "hold" rating to a "buy" rating in a research report on Thursday. DA Davidson dropped their target price on shares of Medifast from $17.00 to $16.50 and set a "neutral" rating on the stock in a report on Wednesday, February 19th.
Get Our Latest Report on Medifast
About Medifast
(
Get Free Report)
Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
Featured Articles
Before you consider Medifast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medifast wasn't on the list.
While Medifast currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
